Breaking News
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
October 23, 2018 - Cancer stem cells use ‘normal’ genes in abnormal ways
October 23, 2018 - Bad Blood: A conversation with investigative reporter John Carreyrou | News Center
October 23, 2018 - As U.S. fertility rates collapse, finger-pointing and blame follow
October 23, 2018 - Researchers develop promising targeted strategy to treat chemo-resistant blood cancer
October 23, 2018 - Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus
October 23, 2018 - Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
October 23, 2018 - 11th World Stroke Congress examines high stroke impact in low- and middle-income countries
October 22, 2018 - Breast cancer survival could be extended with two new drug combinations
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Innovative strategy opens up new avenue of treatment for anthrax infections
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Drug cocktail that increases lifespan discovered
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Study shows potential positive impact of group prenatal care on birth outcomes
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Duration of respiratory disturbances may better predict mortality risk from OSA
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

image_pdfDownload PDFimage_print

For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer. The monoclonal antibody is always used in combination with trastuzumab and chemotherapy. Whereas the first two benefit assessments dealt with the treatment of advanced breast cancer and with neoadjuvant treatment, i.e. treatment administered before surgery, this assessment dealt with the advantages and disadvantages in adjuvant, i.e. supportive treatment of early breast cancer at high risk of recurrence.

The conclusion: For patients under 65 years of age, the combination therapy of pertuzumab, trastuzumab, a taxane, and, if applicable, an anthracycline is not better than the appropriate comparator therapy. There is even a hint of lesser benefit for patients aged 65 or older. A notable positive aspect was the methodologically solid validation of the surrogate outcome “disease-free survival” and the long follow-up observation period for symptoms and health-related quality of life.

APHINITY study showed no significant survival advantage

In its dossier, the drug manufacturer cited a single randomized controlled trial, from which it derived an added benefit of pertuzumab: A majority of the just over 4800 patients in the ongoing APHINITY study concurred with the approval of the drug. All patients had their primary tumours surgically removed before the start of the study. They were then randomly allocated in a 1:1 ratio to the arm with pertuzumab, trastuzumab and chemotherapy, or to the comparator arm with placebo, trastuzumab and chemotherapy. Trastuzumab and pertuzumab are monoclonal antibodies that aim to reduce the risk of recurrence by blocking the epidermal growth factor receptor HER2/neu, which is overexpressed in the cancer cells.

No statistically significant difference was shown between the treatment groups for the patient-relevant outcome “overall survival”. There was an indication of an added benefit of the pertuzumab combination in the morbidity outcome “recurrence”, but hints of lesser benefit for some symptoms. In the outcome category “health-related quality of life”, there were hints of an added benefit in two of nine areas, but also a hint of lesser benefit in one area. In addition, there were some indications of lesser benefit in the category of side effects, e.g. in form of more frequent serious adverse events.

In summary, the negative aspects outweighed the advantages of the new combination; there was even lesser benefit in comparison with the appropriate comparator therapy for patients over 65 years of age.

Up to two years of follow-up

In contrast to very advanced metastatic breast cancer, the treatment goal of early breast cancer is to cure the disease: Many patients still have a long life ahead of them. Many studies in the early benefit assessment hardly allow assessing whether deterioration of a symptom or of health-related quality of life, for example, are of a temporary nature as the data are only recorded during treatment. The present study with its long follow-up observation period for symptoms and quality of life (up to two years after the end of treatment), however, measured these outcomes both during treatment and at some interval after the end of treatment. This kind of study design allows to differentiate between temporary advantages or disadvantages of a treatment and long-term effects.

Methodologically exemplary surrogate validation

Due to the relatively long life expectancy of patients with early breast cancer, a significant advantage in overall survival was not expected to be shown during the study. The manufacturer therefore interpreted the so-called disease-free survival (such as the frequency of recurrences) as surrogate parameter for this outcome and derived an added benefit from it. This was based on the assumption that a positive treatment effect on such a substitute outcome also has a favourable effect on the actually relevant outcome. As it is by no means certain that this is the case, surrogates need to be thoroughly validated. The manufacturer conducted a validation study, where it collected data on disease-free survival and overall survival from other comparable studies and first investigated the strength of the correlation between these two entities.

These other studies differed from the APHINITY study, particularly regarding their comparator therapies. The surrogate validation is still conclusive because these studies also included patients with early breast cancer receiving adjuvant treatment with monoclonal antibodies, and hence the patient populations, the drug class, and the lines of treatment were the same. The correlation determined between disease-free survival and overall survival was of medium strength. Hence the researchers then established the so-called surrogate threshold effect (STE). The STE is the minimum effect on the surrogate that has to be shown to consider an effect on the clinical outcome to still be proven in case of medium correlation.

Effect too small for transferability to overall survival

Conclusions on overall survival based on disease-free survival would only be possible if the treatment effect on the surrogate in the APHINITY study was fully above this threshold. This was not the case, however.

Beate Wieseler, Head of IQWiG’s Drug Assessment Department notes: “The effect on the surrogate outcome was not large enough. Hence it is not certain that there is an effect on the patients’ overall survival, which is the outcome of actual interest.” According to Beate Wieseler, the surrogate validation did not change the assessment result in this assessment. “It does show, however, that the correlation-based validation methods we proposed in our 2010 report on surrogate outcomes, are practicable”, she adds.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the Federal Joint Committee (G-BA). After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.


About author

Related Articles